Gene: MYO18A
Official Full Name: myosin XVIIIAprovided by HGNC
Gene Summary: The protein encoded by this gene can bind GOLPH3, linking the Golgi to the cytoskeleton and influencing Golgi membrane trafficking. The encoded protein is also part of a complex that assembles lamellar actomyosin bundles and may be required for cell migration. [provided by RefSeq, Oct 2016]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO02241 | MYO18A Knockout cell line (HCT 116) | Human | MYO18A | 1:2~1:4 | Negative | Online Inquiry |
KO02242 | MYO18A Knockout cell line (HEK293) | Human | MYO18A | 1:3~1:6 | Negative | Online Inquiry |
MYO18A Gene Knockout Cell Lines are specialized biological reagents engineered to facilitate the study of MYO18A, a member of the myosin superfamily involved in various cellular processes, including cell motility, division, and intracellular transport. These cell lines contain targeted deletions within the MYO18A gene, thus enabling researchers to investigate the functional consequences of MYO18A deficiency on cellular dynamics and signaling pathways.
The primary mechanism by which MYO18A Gene Knockout Cell Lines function involves the lack of MYO18A protein, leading to observable changes in cytoskeletal organization and cellular behavior. By utilizing the CRISPR-Cas9 gene-editing technology, these knockout cell lines ensure precise deletion of the MYO18A gene, allowing researchers to assess its role in cellular processes at a genomic and proteomic level. This type of methodology, focusing on gene function through loss-of-function studies, is crucial in elucidating the mechanisms underlying diseases, such as cancer and neurodegenerative disorders.
From a scientific perspective, these cell lines have significant applications in both research and clinical settings. They are invaluable for drug testing, molecular mechanism investigations, and biomarker discovery, contributing to the advancement of personalized medicine approaches. Furthermore, the ability to observe phenotypic changes in the absence of MYO18A can aid in understanding complex interactions within the cellular environment and pave the way for therapeutic interventions targeting related pathways.
What sets our MYO18A Gene Knockout Cell Lines apart from alternative products is their high specificity and reproducibility, backed by rigorous characterization and validation processes. Unlike other knockout models, our cell lines are developed under stringent conditions that ensure consistent performance across various experimental platforms, enhancing reliability in research outcomes.
For researchers and clinicians focused on the intricacies of cellular dynamics, the MYO18A Gene Knockout Cell Lines represent a vital tool that deepens understanding of fundamental biological processes. Our commitment to quality and innovation in biological product development, combined with comprehensive customer support, underscores our expertise in providing leading-edge solutions that drive scientific discovery and clinical advancements.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.